Amicus Therapeutics to Announce Full-Year 2024 Financial Results on February 19, 2025GlobeNewsWire • 02/10/25
Amicus Therapeutics Announces Presentations and Posters at the 21st Annual WORLDSymposium™ 2025GlobeNewsWire • 02/03/25
NCLA Amicus Brief Asks Fifth Circuit to Uphold Jury-Trial Rights in FDIC Enforcement CasesGlobeNewsWire • 01/23/25
NCLA Amicus Brief Asks Supreme Court to Keep Unlawful Corporate Transparency Act EnjoinedGlobeNewsWire • 01/13/25
Amicus Therapeutics Reports Preliminary 2024 Revenue and Provides 2025 Strategic OutlookGlobeNewsWire • 01/12/25
Amicus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/02/25
Fold, Inc. Announces Up To $30 Million Convertible Note Financing Backed by BitcoinBusiness Wire • 12/30/24
NCLA Amicus Brief Asks Supreme Court to Read Judicial Review Statute Broadly, as Congress Wrote ItGlobeNewsWire • 12/23/24
NCLA Amicus Brief Asks Fifth Circuit to Uphold Block on Unconstitutional Corporate Transparency ActGlobeNewsWire • 12/18/24
Retired Judges' Amicus Brief Supports Judge Newman in NCLA Suit Against Her SuspensionGlobeNewsWire • 12/13/24
Amicus Therapeutics (FOLD) is a Top-Ranked Momentum Stock: Should You Buy?Zacks Investment Research • 12/13/24
Why Is Amicus Therapeutics (FOLD) Down 11.1% Since Last Earnings Report?Zacks Investment Research • 12/09/24
NCLA Amicus Brief Asks Fifth Circuit to Overturn Banking Administration Board's Denial of Jury TrialGlobeNewsWire • 12/03/24
NCLA Amicus Brief Asks Fifth Circuit to Overturn Currency Comptroller's Violation of Jury Trial RightsGlobeNewsWire • 11/13/24
Here's What Key Metrics Tell Us About Amicus Therapeutics (FOLD) Q3 EarningsZacks Investment Research • 11/07/24